Diferencia entre revisiones de «HIV post-exposure prophylaxis»
(→Source) |
Sin resumen de edición |
||
| Línea 18: | Línea 18: | ||
*Common side-effects = constitutional, gastrointestinal | *Common side-effects = constitutional, gastrointestinal | ||
===Specific Regimens (CDC)=== | === Specific Regimens (CDC) === | ||
#Basic | #Basic (2-Drug) | ||
## | ##Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD | ||
## | ##OR, Zidovudine-Lamivudine 300mg/150mg (Combivir): 1 tab PO BID | ||
#Expanded | #Expanded (3-Drug) | ||
##High risk exposures | ##Ritonavir-Lopinavir (Kaletra) | ||
##High risk exposures | |||
##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir) | ##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir) | ||
Revisión del 04:44 24 nov 2012
Workup
- Td
- Hepatitis B PEP for non-vaccinated
- Hepatitis B immunoglobulin and/or vaccine
- Source labs
- Rapid HIV, hep pannel, RPR?
- Exposed labs
- Rapid HIV, hep pannel, RPR?
- Consider HIV PEP
- CBC, C7, LFTs, Icon if considering HIV PEP
^Currently no PEP for Hep C
HIV PEP
- ~79% transmission reduction
- Initiate ASAP (goal = 1-2 hours)
- >36 hours: normally deferred, unless particularly high risk
- Common side-effects = constitutional, gastrointestinal
Specific Regimens (CDC)
- Basic (2-Drug)
- Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
- OR, Zidovudine-Lamivudine 300mg/150mg (Combivir): 1 tab PO BID
- Expanded (3-Drug)
- Ritonavir-Lopinavir (Kaletra)
- High risk exposures
- Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir)
High Risk
Source
- Symptomatic HIV/AIDS
- Acute seroconversion
- High viral load
Exposure
- Deep injuries
- Visible blood on device
- Injuries sustained placing a catheter in a vein/artery
See Also
Source
8/07 DONALDSON
